BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
4/8 — Partial
Priority Review
ELAHERE (mirvetuximab soravtansine) by AbbVie is soravtansine-gynx is an antibody-drug conjugate (adc). First approved in 2022.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELAHERE (mirvetuximab soravtansine-gynx) is an antibody-drug conjugate (ADC) that binds folate receptor alpha (FRα) on cancer cells and delivers a microtubule-disrupting payload (DM4) intracellularly, triggering cell cycle arrest and apoptosis. Approved in November 2022, it represents a targeted mechanism for FRα-expressing malignancies, primarily ovarian cancer. The chimeric IgG1 backbone enables internalization-dependent cytotoxicity with a cleavable linker for controlled drug release.
Peak
Peak lifecycle stage indicates established commercial infrastructure with AbbVie's oncology sales team executing mature promotional strategies and managed care negotiations.
Mechanism of Action
soravtansine-gynx is an antibody-drug conjugate (ADC). The antibody is a chimeric IgG1 directed against folate receptor alpha (FRα). The small molecule, DM4, is a microtubule inhibitor attached to the antibody via a cleavable linker. Upon binding to FRα, mirvetuximab soravtansine-gynx is…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer
Started Oct 2026
500 enrolled
Platinum-Resistant FRα-Positive Ovarian CancerPlatinum-Resistant FRα-Positive Fallopian Tube CancerPlatinum-Resistant FRα-Positive Peritoneal Cancer
A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting
Started Jun 2026
69 enrolled
Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian CancerFolate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube CancerFolate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Started Dec 2025
1,100 enrolled
Epithelial Ovarian Cancer
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Started Nov 2025
140 enrolled
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer+1 more
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Started Nov 2025
400 enrolled
Ovarian Cancer
Worked on ELAHERE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.